Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Opening Session Panel Discussion

Advertisement

Advertisement




Aug
20
Today In Oncology
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events
Charles WM Roberts Named President and Chief Executive Officer of St. Jude Children’s Research Hospital
Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?
Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo